Skip to content
DraconiticResearch
Search Sources API
197,768 studies31 sourcesUpdated 42 min ago
Peer-reviewedCC BY-NC-NDJAMA ophthalmology

Variables Associated With Faricimab Treatment Durability in Neovascular Age-Related Macular Degeneration : A Post Hoc Analysis of the TENAYA and LUCERNE Trials

  • Colin S. Tan1
  • Benjamin Bakall2
  • Adrian Hock Chuan Koh3
  • Priya Vakharia4
  • Deepak Sambhara5
  • Mathias Maier6
  • Quresh Mohamed7
  • Ming Yang8
  • Philippe Margaron9
  • Shriji Patel8
  • Eric H. Souied10
10 affiliations
  1. 1Fundus Image Reading Center, National Healthcare Group Eye Institute, Tan Tock Seng Hospital, Singapore
  2. 2Associated Retina Consultants, Phoenix, Arizona
  3. 3Eye & Retina Surgeons, Camden Medical Centre, Singapore
  4. 4Retina Vitreous Associates of Florida, Palm Harbor
  5. 5Eye Clinic of Wisconsin, Wausau
  6. 6Universitätsklinikum rechts der Isar, Technical University of Munich, Munich, Germany
  7. 7Cheltenham General Hospital, Gloucestershire Hospitals NHS Foundation Trust, Gloucester, United Kingdom
  8. 8Genentech, Inc, South San Francisco, California
  9. 9F. Hoffmann-La Roche Ltd, Basel, Switzerland
  10. 10University Paris Est Creteil, Creteil, France
Read full textCite

Related

  1. Real-world anatomical and functional outcomes following Faricimab therapy in neovascular age-related macular degeneration: a one-year observational study
    Settimio Rossi, Carlo Gesualdo, Maria Consiglia Trotta +6
    Frontiers in medicinePeer-reviewedCC BYFull textGeneral medicineEurope PMC
  2. Progressive intraocular inflammation with anterior scleritis following intravitreal Faricimab for neovascular age-related macular degeneration: a case report
    Ching-Hua Hsu, Acer I-Hung Chen, Chien-Hsiung Lai +1
    BMC OphthalmologyPeer-reviewedCC BYFull textGeneral medicineDOAJ
  3. DTCAMD, a disease-associated truncated form of CRYAB in neovascular age-related macular degeneration: a potential driver of subretinal fibrosis
    E. Yu, S. M. Gu, J. Jin +2
    bioRxivPreprintCC BY-NC-NDFull textGeneral medicinebioRxiv
  4. Effectiveness and Treatment Burden of Faricimab in Neovascular AMD: A Real-World Analysis of Treatment-Naïve and Previously Treated Patients in Poland
    Michał Seweryn, Marek Rękas, Małgorzata Figurska
    Journal of clinical medicinePeer-reviewedCC BYFull textGeneral medicineEurope PMCCrossref
  5. Association Between the Social Deprivation Index and Neovascular Age-Related Macular Degeneration Outcomes
    Rohini Dasan, Mike Y. Chen, Jeanette Du +4
    Journal of Vitreoretinal DiseasesPeer-reviewedLicence not statedFull text1 citedGeneral medicinePMC

Cite

BibTeXRIS
BibTeX
@article{tan2026variables,
  title = {{Variables Associated With Faricimab Treatment Durability in Neovascular Age-Related Macular Degeneration : A Post Hoc Analysis of the TENAYA and LUCERNE Trials}},
  author = {Colin S. Tan and Benjamin Bakall and Adrian Hock Chuan Koh and Priya Vakharia and Deepak Sambhara and Mathias Maier and Quresh Mohamed and Ming Yang and Philippe Margaron and Shriji Patel and Eric H. Souied},
  journal = {JAMA ophthalmology},
  year = {2026},
  month = oct,
  url = {https://europepmc.org/article/PMC/PMC13673382},
  note = {CC BY-NC-ND},
}
RIS
TY  - JOUR
TI  - Variables Associated With Faricimab Treatment Durability in Neovascular Age-Related Macular Degeneration : A Post Hoc Analysis of the TENAYA and LUCERNE Trials
AU  - Colin S. Tan
AU  - Benjamin Bakall
AU  - Adrian Hock Chuan Koh
AU  - Priya Vakharia
AU  - Deepak Sambhara
AU  - Mathias Maier
AU  - Quresh Mohamed
AU  - Ming Yang
AU  - Philippe Margaron
AU  - Shriji Patel
AU  - Eric H. Souied
PY  - 2026
DA  - 2026/10/15
JO  - JAMA ophthalmology
UR  - https://europepmc.org/article/PMC/PMC13673382
SN  - 2168-6165
SN  - 2168-6173
ER  -